Implications of delayed initiation of radiotherapy: Accelerated repopulation after induction chemotherapy for stage III non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 11, 2011, Pages 1857-1864

  Chen, Chien P ^a   Weinberg, Vivian K ^b   Jahan, Thierry M ^c   Jablons, David M ^a   Yom, Sue S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Helen Diller Family Comprehensive Cancer Centre   (United States)

^c School of Medicine   (United States)

Author keywords

Induction chemotherapy; Radiation; Repopulation; Stage III lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADULT; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL POPULATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION DOSE; RADIATION RESPONSE; RETROSPECTIVE STUDY; REVIEW; STATISTICAL SIGNIFICANCE; THERAPY DELAY; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME;

EID: 80054963066     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318229a41e     Document Type: Article

References (37)

1. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002;20:247-253. (Pubitemid 34032618)
2. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994;86:673-680.
3. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330:153-158. (Pubitemid 24026882)
4. McAleer MF, Moughan J, Byhardt RW, et al. Does response to induction chemotherapy predict survival for locally advanced non-small-cell lung cancer? Secondary analysis of RTOG 8804/8808. Int J Radiat Oncol Biol Phys 2010;76:802-808.
5. Friedel G, Budach W, Dippon J, et al. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study. J Clin Oncol 2010;28:942-948.
6. Hehr T, Friedel G, Steger V, et al. Neoadjuvant chemoradiation with paclitaxel/carboplatin for selected stage III non-small-cell lung cancer: long-term results of a trimodality phase II protocol. Int J Radiat Oncol Biol Phys 2010;76:1376-1381.
7. Felip E, Rosell R, Maestre JA, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol 2010;28:3138-3145.
8. Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2181-2190.
9. Curran WJ, Scott, CB, Langer, CJ, et al. Long-term benefit is observed in phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 2003;22:621.
10. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-2699. (Pubitemid 29415225)
11. Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005;23:5883-5891.
12. Vokes EE, Herndon JE 2nd, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007;25:1698-1704. (Pubitemid 46797950)
13. El Sharouni SY, Kal HB, Battermann JJ. Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy. Br J Cancer 2003;89:2184-2189. (Pubitemid 38167997)
14. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 2005;5:516-525. (Pubitemid 40942828)
15. Fowler JF, Chappell R. Non-small cell lung tumors repopulate rapidly during radiation therapy. Int J Radiat Oncol Biol Phys 2000;46:516-517. (Pubitemid 30067805)
16. Saunders M, Dische S, Barrett A, et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol 1999;2:137-148. (Pubitemid 29461081)
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
18. Schwartz M. A biomathematical approach to clinical tumor growth. Cancer 1961;14:1272-1294.
19. Detterbeck FC, Gibson CJ. Turning gray: the natural history of lung cancer over time. J Thorac Oncol 2008;3:781-792.
20. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
21. Rowell NP, O'rourke NP. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2004:CD002140.
22. Zatloukal P, Petruzelka L, Zemanova M, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004;46:87-98. (Pubitemid 39201387)
23. Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradio-therapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 2005;23:5910-5917.
24. Rosenthal DI, Liu L, Lee JH, et al. Importance of the treatment package time in surgery and postoperative radiation therapy for squamous carcinoma of the head and neck. Head Neck 2002;24:115-126. (Pubitemid 34111508)
25. Saunders M, Dische S, Barrett A, et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 1997;2: 161-165.
26. Hatton M, Nankivell M, Lyn E, et al. Induction chemotherapy and continuous hyperfractionated accelerated radiotherapy (CHART) for patients with locally advanced inoperable non-small-cell lung cancer: The MRC INCH Randomized Trial. Int J Radiat Oncol Biol Phys. 2010 Oct 5. [Epub ahead of print].
27. Watanabe H, Yamamoto S, Kunitoh H, et al. Tumor response to chemotherapy: the validity and reproducibility of RECIST guidelines in NSCLC patients. Cancer Sci 2003;94:1015-1020. (Pubitemid 37508986)
28. Ak G, Metintas M, Metintas S, et al. Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma. Eur J Radiol 2010;74:130-135.
29. Sohaib SA, Turner B, Hanson JA, et al. CT assessment of tumour response to treatment: comparison of linear, cross-sectional and volumetric measures of tumour size. Br J Radiol 2000;73:1178-1184.
30. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006;42:1031-1039.
31. Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. JNucl Med 2009;50(Suppl 1):122S-150S.
32. Sawabata N, Ohta M, Maeda H, et al. Prognostic significance of persistent mediastinal metastasis following induction therapy in large (> or = 2 cm) N2 or N3 non-small cell lung cancer. Jpn J Thorac Cardiovasc Surg 2003;51:123-129. (Pubitemid 38166295)
33. Pisters KM, Kris MG, Gralla RJ, et al. Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials. J Clin Oncol 1993;11:1757-1762. (Pubitemid 23277329)
34. Trodella L, Granone P, Valente S, et al. Neoadjuvant concurrent ra-diochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long-term results according to downstaging. Ann Oncol 2004; 15:389-398. (Pubitemid 38444541)
35. Dooms C, Verbeken E, Stroobants S, et al. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography. J Clin Oncol 2008;26: 1128-1134.
36. Bueno R, Richards WG, Swanson SJ, et al. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg 2000;70:1826-1831. (Pubitemid 32015269)
37. Birchard KR, Hoang JK, Herndon JE Jr, et al. Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival. Cancer 2009;115:581-586.